Antiretroviral
DTG/3TC for HIV-1 in Adolescents
This trial tests a new two-drug pill for HIV-infected adolescents who haven't had treatment before. The pill combines DTG and 3TC, which work together to stop the virus from multiplying. The goal is to see if this simpler treatment is effective and safe over time. Dolutegravir (DTG) and lamivudine (3TC) have shown high efficacy and tolerability in both new and experienced HIV-positive patients, and are recommended as an alternative to more complex treatments to reduce long-term toxicity and costs.
Behavioral Intervention
Text Messaging for HIV Testing
This trial will investigate if sending text messages can encourage HIV testing among adolescent sexual minority men and transgender and gender diverse teens. Participants will be randomly assigned to either receive text message intervention or information only. The
Behavioral Intervention
Text Messaging for HIV Prevention
This trial will last for 3 years and aims to determine if text messages can effectively help prevent HIV in dental patients. The study will involve 266 participants from 4 community health centers who will either
Popular Filters
Trials for HIV Patients
Behavioural Intervention
Provider Training and Patient Education for HIV Prevention
This trial aims to improve the rate of new PrEP prescriptions at a healthcare system by testing different intervention components, such as training for providers and patient education, in primary care settings. The goal is to
Behavioural Intervention
Telehealth Support for HIV
This trial will assess a program to help young men living with HIV in online delivery to improve social connections and their health. It has 3 phases, engaging a community, a randomized clinical trial, and evaluation. Participants will meet with a study team and provide consent.
Nucleoside/nucleotide reverse transcriptase inhibitor
F/TAF for HIV-Controlled Pediatric Patients
This trial is studying the safety and effectiveness of a new HIV drug in children and adolescents who are already taking other HIV drugs and have had their HIV infection controlled for at least six months.
Trials for HIV/AIDS Patients
Cancer Vaccine
HPV Vaccine for HIV/AIDS
This trial will study the nonavalent HPV vaccine in adults with HIV to see if it produces a similar antibody response to the vaccine as people without HIV, and to observe short-term clinical outcomes of HPV infections.
Virus Therapy
Gene Therapy for Lymphoma in HIV Patients
This trial is testing a new gene therapy for HIV-related lymphoma. The therapy involves inserting anti-HIV genes into the patient's stem cells in the laboratory. The goal is to make the patient's immune cells more resistant to HIV-1 and prevent new immune cells from getting infected with HIV-1.
Behavioral Intervention
Bilingual Intervention for HIV/AIDS-Related Food Insecurity
This trial tests a program to help people with HIV who don't have enough food. It aims to improve their blood sugar levels by ensuring they have enough to eat. The goal is to reduce the risk of diabetes and related health issues.
Phase 3 Trials
Nucleoside/nucleotide reverse transcriptase inhibitor
F/TAF for HIV-Controlled Pediatric Patients
This trial is studying the safety and effectiveness of a new HIV drug in children and adolescents who are already taking other HIV drugs and have had their HIV infection controlled for at least six months.
Antiretroviral
DOR/ISL Switch for HIV
This trial is testing if switching to a new HIV treatment is as good or better than continuing the current treatment. The study focuses on people with HIV-1 who are already on a specific treatment. The new treatment works by reducing the amount of HIV in the blood, helping to keep the immune system healthy.
Antiretroviral
DOR/ISL for HIV
This trial is testing a new once-daily pill for HIV-1 infection. The pill contains two drugs, doravirine and islatravir. The trial will compare the new pill to a currently available pill that contains three drugs, bictegravir, emtricitabine, and tenofovir alafenamide. The trial will last 48 weeks and the primary outcome will be the percentage of participants with HIV-1 RNA <50 copies/mL at Week 48.
Antiretroviral Therapy
DOR/ISL for HIV/AIDS
This trial will compare the safety and efficacy of switching to a new drug regimen (MK-8591A) versus continuing the current drug regimen (BIC/FTC/TAF) in HIV-1 infected individuals who are currently virally suppressed. The primary hypothesis is that the new drug regimen will be at least as effective as the current drug regimen in maintaining viral suppression.
Trials With No Placebo
Behavioural Intervention
Provider Training and Patient Education for HIV Prevention
This trial aims to improve the rate of new PrEP prescriptions at a healthcare system by testing different intervention components, such as training for providers and patient education, in primary care settings. The goal is to
Behavioural Intervention
Telehealth Support for HIV
This trial will assess a program to help young men living with HIV in online delivery to improve social connections and their health. It has 3 phases, engaging a community, a randomized clinical trial, and evaluation. Participants will meet with a study team and provide consent.
Cancer Vaccine
HPV Vaccine for HIV/AIDS
This trial will study the nonavalent HPV vaccine in adults with HIV to see if it produces a similar antibody response to the vaccine as people without HIV, and to observe short-term clinical outcomes of HPV infections.
Frequently Asked Questions
Introduction to hiv
What are the top hospitals conducting hiv research?
When it comes to cutting-edge clinical trials in the field of HIV research, several top hospitals are leading the way. The GSK Investigational Sites spread across multiple locations have been at the forefront of this battle against HIV. In Dallas, researchers are currently conducting five active trials for HIV, marking a significant commitment to finding new treatments and solutions for this condition. Similarly, in Toronto, another GSK Investigational Site is actively engaged in five ongoing HIV trials. These sites are dedicated to investigating novel approaches to combat the virus and improve patient outcomes. Meanwhile, Los Angeles boasts four active trials conducted by their own GSK Investigational Site, which focuses on developing innovative strategies and therapies for individuals living with HIV.
In Bakersfield and Orlando as well there exist dynamic institutions focused on contributing significantly towards fighting against this disease through rigorous investigations coordinated by respective local branches of GSK's investigative site; both facilities have initiated four studies each from within their premises aimed explicitly comprehending different aspects associated with prevention or treatment methods designed more efficiently addressing concerns related to HIv.
These committed hospitals reflect a collective determination among researchers worldwide who relentlessly work towards unraveling the complexities surrounding HIV transmission, progression, treatment options while simultaneously aiming at discovering potential breakthroughs that will ultimately lead us closer to eradicating this devastating disease once and for all
Which are the best cities for hiv clinical trials?
When it comes to HIV clinical trials, several cities in the United States and Canada offer exceptional research opportunities. Los Angeles, California leads with 15 active trials studying treatments such as DOR/ISL, GSK3810109A, and Islatravir. Orlando, Florida and Dallas, Texas closely follow with 11 ongoing studies focused on similar interventions. In Canada, both Toronto, Ontario and Montreal, Quebec boast 10 active trials exploring treatments like DOR/ISL and GSK3810109A. These cities serve as vital hubs for groundbreaking research that advances our understanding of HIV treatment options and provides hope for individuals living with this condition.
Which are the top treatments for hiv being explored in clinical trials?
Exciting advancements are underway in HIV research, with one treatment leading the way. Tele-B6 has emerged as a promising contender, currently being explored in an active clinical trial dedicated to HIV. Although it is still early in its journey, with just one all-time trial and first listed in 2023, the potential of this treatment is generating considerable interest and anticipation within the scientific community. As researchers continue their tireless efforts, we eagerly await further developments that could shape the future of HIV treatment.
What are the most recent clinical trials for hiv?
Exciting developments are underway in the realm of HIV research, with recent clinical trials offering new insights and potential treatments. One such trial focuses on participants receiving VH3810109 in combination with Cabotegravir, a Phase 2 study that became available on August 17th, 2023. Another promising trial involves participants receiving DTG/3TC fixed-dose combination (FDC) for HIV, which entered Phase 3 and became available on July 7th and July 6th respectively. Additionally, there have been Phase 3 trials evaluating the efficacy of DOR/ISL as a treatment option for HIV patients; these studies were made accessible to the public on March 17th and February 20th respectively. These groundbreaking clinical investigations hold immense potential in enhancing our understanding of HIV management and bringing us closer to improved outcomes for those living with this condition.
What hiv clinical trials were recently completed?
Several notable clinical trials in the field of HIV have recently concluded, representing significant progress in this area of research. Notably, a trial evaluating the efficacy and safety of a novel antiretroviral therapy completed successfully. This study marks an important milestone in advancing treatment options for individuals living with HIV. Additionally, another trial focusing on innovative prevention strategies has reached its conclusion, offering valuable insights into reducing transmission rates among high-risk populations. These recent clinical trials signify the continuous efforts to enhance our understanding and address the challenges posed by HIV/AIDS.